Cencora Reports Strong Q1 Fiscal 2026 Results, Details $4.6B OneOncology Acquisition & 9% Dividend Hike
Summary
Cencora reported strong Q1 fiscal 2026 earnings with significant revenue and net income growth, provided details on its $4.6 billion OneOncology acquisition and related financing, and announced a 9% dividend increase.
Key Events
-
Strong Q1 Fiscal 2026 Financial Performance
Revenue increased by 5.5% to $85.93 billion, net income attributable to Cencora, Inc. grew 14.5% to $559.6 million, and diluted EPS rose 14.8% to $2.87 for the three months ended December 31, 2025.
-
Details on $4.6 Billion OneOncology Acquisition
The filing provides comprehensive details on the $4.6 billion cash acquisition of OneOncology, completed on February 2, 2026, and the associated new debt financing, including a $1.5 billion Multi-Year Term Loan and a $3.0 billion 364-Day Term Loan, along with an expanded $5.5 billion revolving credit facility.
-
Quarterly Dividend Increased by 9%
The Board of Directors increased the quarterly cash dividend on common stock by 9%, from $0.55 to $0.60 per share, in November 2025.
-
Goodwill Impairment on Divested Business
The company recorded a $165.7 million goodwill impairment related to its U.S. Consulting Services business, which has been classified as held for sale.
Analysis
Cencora, Inc. filed its Q1 fiscal 2026 10-Q, providing detailed financial results and corporate updates. The company reported robust revenue growth of 5.5% to $85.93 billion and a significant 14.5% increase in net income attributable to Cencora, Inc. to $559.6 million, with diluted EPS rising 14.8% to $2.87. This filing elaborates on the previously announced $4.6 billion acquisition of OneOncology, detailing the new debt financing facilities secured to fund the transaction, including a $1.5 billion Multi-Year Term Loan and a $3.0 billion 364-Day Term Loan, alongside an increased $5.5 billion revolving credit facility. Additionally, the company disclosed a 9% increase in its quarterly dividend to $0.60 per share and a $165.7 million goodwill impairment related to its U.S. Consulting Services business, which is classified as held for sale. Several executives also adopted Rule 10b5-1 trading arrangements for future share sales, representing a modest portion of the company's market capitalization.
At the time of this filing, COR was trading at $329.33 on NYSE in the Trade & Services sector, with a market capitalization of approximately $64.1B. The 52-week trading range was $237.71 to $377.54. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.